Source: PMLiVE

Exelixis: FDA approves Exelixis' Cabometyx to treat advanced neuroendocrine tumours

Approximately 380,000 people in the US were affected by NETs in the US in 2024

Read full article »
Exelixis's Competitors | Exelixis's News | Exelixis's Financials
Stay up-to-date with the latest news on Exelixis
Annual Revenue
$1.0-5.0B
Employees
1.0-5.0K
Michael M. Morrissey's photo - President & CEO of Exelixis

President & CEO

Michael M. Morrissey

CEO Approval Rating

51/100

Read more
Stay up-to-date with the latest news on Exelixis